ZIM Laboratories has received approval from Board of Directors to invest upto Euro 1,50,000 in the equity shares of SIA ZIM Laboratories, wholly owned subsidiary of the company. The investment in equity shares of SIA ZIM Laboratories is with an objective of expansion and development of business in the European region.
With the proposed investment, the Company’s shareholding in SIA ZIM Laboratories remains at 100%. The Board of Directors in their meeting held on September 30, 2024 have considered and inter alia approved the same.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develop generic pharmaceutical products.
